Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi

CAFEROGLU AKIN, Zeynep; Onur, Aslı; Hatipoglu, Nihal

doi:10.25048/tudod.788391

Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi

Aslı ONUR, (Erciyes Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Kayseri, Türkiye)

Zeynep CAFEROĞLU, (Erciyes Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Kayseri, Türkiye)

Nihal HATİPOĞLU (Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Kayseri, Türkiye)

Türkiye Diyabet ve Obezite Dergisi

18 4

Yıl: 2021 Cilt: 5 Sayı: 1 Sayfa Aralığı: 59 - 67 Metin Dili: Türkçe DOI: 10.25048/tudod.788391 İndeks Tarihi: 03-01-2022

Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi

Öz:

Diabetes mellitus (DM) kronik metabolik bir hastalık olduğu ve oruç sırasında hipoglisemi, hiperglisemi, dehidratasyon ve koagulasyon gibi riskler taşıdığından Ramazan orucu için riskli bir durum olarak kabul edilir. Ramazan ayı boyunca Müslümanlar, şafaktan gün batımına kadar geçen süre boyunca yiyecekten, içecekten, sigaradan ve cinsel ilişkiden uzak dururlar. Ramazan ayı 29-30 gün sürmekte ve oruç tutulan süre coğrafi konuma göre 10 ila 20 saate kadar uzun bir zaman dilimini kapsamaktadır. Oruç tutmak için şart, sağlıklı olmak ve kronik hastalığa sahip olmamaktır. Ancak, dini zorunluluk olduğu ve manevi fayda sağlayacağı düşüncesiyle kronik hastalığı olan çoğu birey de oruç tutmayı istemektedir. Ramazan ayında oruç sırasında hipoglisemi korkusu da yaygın bir sorundur. Bununla birlikte, klinik uygulamada DM’li bireylerin çoğu oruç tutmayı tercih etmektedir. Bu nedenle sağlık uzmanlarının çeşitli risklere karşı DM’li bireyleri koruması, hipoglisemik ve hiperglisemik olayları önlemek için bu özel durumlara özgü eğitim vermesi zorunluluğu kaçınılmazdır. Bu derleme, sağlık uzmanlarının Ramazan ayında oruç tutmayı planlayan tip 1 ve tip 2 DM’li yetişkin bireylere kılavuzların önerileri doğrultusunda risk sınıflandırması, eğitim, farmakoterapi ve kan şekeri takibi, ilaç ve doz ayarlaması gibi önerilerde bulunabilmek için hazırlanmıştır.

Anahtar Kelime:

Management of Diabetes in Individuals with Diabetes who are Fasting During Ramadan

Öz:

Fasting, which is important in many religions, is also one of the five pillars of Islam. During the month of Ramadan, Muslims do not eat, drink, smoke and abstain from sexual activity from dawn to sunset. The month of Ramadan lasts for 29-30 days and the fasting period ranges from 10 to 20 hours depending on geographic location. The condition for fasting is to be healthy and having no chronic illness. However, with the thought that it is a religious obligation and will provide spiritual benefit, most individuals with chronic diseases also want to fast. Diabetes mellitus (DM) is considered a high risk condition for fasting in Ramadan, as it is a chronic metabolic disease and carries risks such as hypoglycemia, hyperglycemia, dehydration and coagulopathy during fasting. Fear of hypoglycemia is a common problem during fasting on holy month Ramadan. However, in clinical practice, most individuals with DM prefer to fast. Therefore, healthcare professionals must provide education sessions to protect individuals with DM against various risks and help prevent hypoglycemic as well as hyperglycemic events. This review has been prepared for health professionals in order to make recommendations such as dose adjustments, risk stratification, diabetes patient education, updating pharmacotherapy and how to make blood glucose monitoring according with the recommendations of the guidelines for adults with type 1 and type 2 DM who plan to fast during Ramadan.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Lessan N, Ali T. Energy metabolism and intermittent fasting: The ramadan perspective. Nutrients. 2019;11(5):1192.
2. Bener A, Al-Hamaq AOAA, Öztürk M, Çatan F, Haris PI, Rajput KU, et al. Effect of ramadan fasting on glycemic control and other essential variables in diabetic patients. Ann Afr Med. 2018;17(4):196-202.
3. Bajaj HS, Abouhassan T, Ahsan MR, Arnaout A, Hassanein M, Houlden RL, et al. Diabetes Canada position statement for people with types 1 and 2 diabetes who fast during Ramadan. Can J Diabetes. 2019;43(1):3-12.
4. Grajower MM, Horne BD. Clinical management of intermittent fasting in patients with diabetes mellitus. Nutrients. 2019;11(4):1-11.
5. Salti I, Bénard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C, et al. A population-based study of diabetes and its characteristics during the fasting month of ramadan in 13 countries: Results of the epidemiology of diabetes and ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306-2311.
6. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017;126:303-316.
7. Tan C, Yong AML, Haji Mohamad MA, Abdul Rahman H, Naing L. Fasting in Ramadan of Muslim patients with diabetes Mellitus, and knowledge and practice in relation to diabetes control in Brunei. Diabetes Res Clin Pract. 2018;144:171-176.
8. Ibrahim M, Davies MJ, Ahmad E, Annabi FA, Eckel RH, BaEssa EM, et al. Recommendations for management of diabetes during Ramadan: Update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Res Care. 2020;8(1):1-14.
9. Jabbar A, Hassanein M, Beshyah SA, Boye KS, Yu M, Babineaux SM. CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents. Diabetes Res Clin Pract. 2017;132:19-26.
10. Malik U, Mahmood N, Khan KA, Hameed M, Randhawa FA, Salman S, et al. Glycaemic control of type 2 diabetic patients during Ramazan fasting. J Ayub Med Coll Abbottabad. 2017;29(1):102-106.
11. Rashid F, Abdelgadir E. A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting. Diabetes Metab Syndr Clin Res Rev. 2019;13(2):1413-1429.
12. Ahmedani MY, Haque MS, Basit A, Fawwad A, Alvi SFD. Ramadan Prospective Diabetes Study: The role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med. 2012;29(6):709-715.
13. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan education and awareness in diabetes (READ) programme for Muslims with type 2 diabetes who fast during Ramadan. Diabet Med. 2010;27(3):327-331.
14. Gad H, Al-Muhannadi H, Purra H, Mussleman P, Malik RA. The effect of Ramadan focused education on patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020;162:108122.
15. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002;58(1):45-53.
16. Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, et al. A randomized controlled trial comparing the GLP‐1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab. 2014;16(6):527-536.
17. Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berrah A, Omar M, et al. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): A randomized trial. Diabetes Obes Metab. 2016;18(10):1025-1033.
18. Hassanein M, Buyukbese MA, Malek R, Pilorget V, Naqvi M, Berthou B, et al. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract. 2020;166:108189.
19. Josse RG, Chiasson J-L, Ryan EA, Lau DCW, Ross SA, Yale J-F, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003;59(1):37-42.
20. DiNicolantonio JJ, Bhutani J, O’Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart. 2015;2(1):e000327.
21. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case-control analysis. Diabetes Care. 2008;31(11):2086-2091.
22. Wright AD, Cull CA, Macleod KM, Holman RR, Group U. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006;20(6):395-401.
23. Devendra D, Gohel B, Bravis V, Hui E, Salih S, Mehar S, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63(10):1446-1450.
24. Halimi S, Levy M, Huet D, Quéré S, Dejager S. Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: Insights from the VERDI study. Diabetes Ther. 2013;4(2):385-398.
25. Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman‐ Boehm I, Kaddaha G, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial. Int J Clin Pract. 2011;65(11):1132-1140.
26. Aravind SR, Tayeb K Al, Ismail SB, Shehadeh N, Kaddaha G, Liu R, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: A five-country observational study. Curr Med Res Opin. 2011;27(6):1237-1242.
27. Wan Seman WJ, Kori N, Rajoo S, Othman H, Wahab NA, Sukor N, et al. Switching from sulphonylurea to a sodiumglucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes Obes Metab. 2016;18(6): 628-632.
28. Hassanein M, Bashier A, Randeree H, Abouelmagd M, AlBaker W, Afandi B, et al. Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes Res Clin Pract. 2020;169:108465.
29. Papanas N, Katsiki N, Hatzitolios AI, Maltezos E. Pioglitazone: A valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12(10):1457-1461.
30. Al‐Arouj M, Hassoun AAK, Medlej R, Pathan MF, Shaltout I, Chawla MS, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: The VIRTUE study. Int J Clin Pract. 2013;67(10):957-963.
31. Abdelgadir EIE, Hafidh K, Basheir AMK, Afandi BO, Alawadi F, et al. Comparison of incidences, hospital stay and precipitating factors of diabetic ketoacidosis in Ramadan and the following month in three major hospitals in United Arab Emirates. A Prospective Observational Study. J Diabetes Metab. 2015;6:514.
32. Loh HH, Lim LL, Loh HS, Yee A. Safety of Ramadan fasting in young patients with type 1 diabetes: A systematic review and meta-analysis. J Diabetes Investig. 2019;10(6):1490-1501.
33. Frier BM. Hypoglycaemia in diabetes mellitus: Epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711- 722.
34. Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al MA, Akram J, et al. Treatment of type 1 diabetes with insulin lispro during Ramadan. Diabetes Metab. 2001;27(4 Pt 1):482-486.
35. Alamoudi R, Alsubaiee M, Alqarni A, Saleh Y, Aljaser S, Salam A, et al. Comparison of insulin pump therapy and multiple daily injections insulin regimen in patients with type 1 diabetes during Ramadan fasting. Diabetes Technol Ther. 2017;19(6):349-354.
36. Masood SN, Masood Y, Mumtaz SN, Maqsood A, Hakim R, Shaikh Z, et al. Ramadan fasting related awareness, practices and experiences of a representative group of Urban Pakistani Diabetics. Pak J Med Sci. 2012;28: 432-436.
37. Eid YM, Sahmoud SI, Abdelsalam MM, Eichorst B. Empowerment-based diabetes self-management education to maintain glycemic targets during ramadan fasting in people with diabetes who are on conventional insulin: A feasibility study. Diabetes Spectr. 2017;30(1):36-42.
38. Kaplan W, Afandi B. Blood glucose fluctuation during ramadan fasting in adolescents with type 1 diabetes: Findings of continuous glucose monitoring. Diabetes Care. 2015;38(10):e162-163.

APA	Onur A, CAFEROGLU AKIN Z, Hatipoglu N (2021). Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. , 59 - 67. 10.25048/tudod.788391
Chicago	Onur Aslı,CAFEROGLU AKIN Zeynep,Hatipoglu Nihal Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. (2021): 59 - 67. 10.25048/tudod.788391
MLA	Onur Aslı,CAFEROGLU AKIN Zeynep,Hatipoglu Nihal Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. , 2021, ss.59 - 67. 10.25048/tudod.788391
AMA	Onur A,CAFEROGLU AKIN Z,Hatipoglu N Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. . 2021; 59 - 67. 10.25048/tudod.788391
Vancouver	Onur A,CAFEROGLU AKIN Z,Hatipoglu N Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. . 2021; 59 - 67. 10.25048/tudod.788391
IEEE	Onur A,CAFEROGLU AKIN Z,Hatipoglu N "Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi." , ss.59 - 67, 2021. 10.25048/tudod.788391
ISNAD	Onur, Aslı vd. "Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi". (2021), 59-67. https://doi.org/10.25048/tudod.788391

APA	Onur A, CAFEROGLU AKIN Z, Hatipoglu N (2021). Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. Türkiye Diyabet ve Obezite Dergisi , 5(1), 59 - 67. 10.25048/tudod.788391
Chicago	Onur Aslı,CAFEROGLU AKIN Zeynep,Hatipoglu Nihal Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. Türkiye Diyabet ve Obezite Dergisi 5, no.1 (2021): 59 - 67. 10.25048/tudod.788391
MLA	Onur Aslı,CAFEROGLU AKIN Zeynep,Hatipoglu Nihal Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. Türkiye Diyabet ve Obezite Dergisi , vol.5, no.1, 2021, ss.59 - 67. 10.25048/tudod.788391
AMA	Onur A,CAFEROGLU AKIN Z,Hatipoglu N Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. Türkiye Diyabet ve Obezite Dergisi . 2021; 5(1): 59 - 67. 10.25048/tudod.788391
Vancouver	Onur A,CAFEROGLU AKIN Z,Hatipoglu N Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi. Türkiye Diyabet ve Obezite Dergisi . 2021; 5(1): 59 - 67. 10.25048/tudod.788391
IEEE	Onur A,CAFEROGLU AKIN Z,Hatipoglu N "Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi." Türkiye Diyabet ve Obezite Dergisi , 5, ss.59 - 67, 2021. 10.25048/tudod.788391
ISNAD	Onur, Aslı vd. "Ramazan Ayında Oruç Tutan Diyabetli Bireylerde Diyabetin Yönetimi". Türkiye Diyabet ve Obezite Dergisi 5/1 (2021), 59-67. https://doi.org/10.25048/tudod.788391